A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.

Trial Profile

A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Pritelivir (Primary) ; Valaciclovir
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Sponsors AiCuris
  • Most Recent Events

    • 12 Nov 2014 Planned number of patients changed from 90 to 98.
    • 09 Sep 2014 Primary endpoint (Within-subject genital HSV mucocutaneous shedding rate) has been met according to results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 09 Sep 2014 Results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top